BioWorld MedTech

March 7, 2011

High risk, narrow markets stunting growth for MDx

VIENNA – The bubble of hype surrounding molecular diagnostics (MDx) has burst, leaving Fabian Kiessling, MD, a lone voice still preaching its promise at this radiology congress. (Medical Device Daily) Read More

FDA clears IVD assays from Wako for liver cancer risk

Washington roundup: Medtronic needles CMS into reopening MRI/EP coverage

When a deal value deferred by milestones is still a good deal

Report from Europe: Medtronic launches Achieve mapping catheter in Europe

HIT roundup: TotalQuality certified as EHR technology reporting module

Court Report: Bovie settles patent suit with Medtronic, Salient Surgical

Patent watch: Biolase wins new U.S. patent for treating eye conditions

Med-Tech Notes

Product Briefs

FDA issues a Class I recall of Cook catheter component

Agreements/contracts: ScandiDos Delta4PT to use Varian's RapidArc technology

MDD's Neurology Extra

Today's news in brief

BioWorld

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...